Review

British Journal of Cancer (2000) 82, 1371–1380. doi:10.1054/bjoc.1999.1075 www.bjcancer.com
Published online 21 March 2000

Chemotherapy for high-grade gliomas

E Galanis1 and J Buckner1

1Division of Medical Oncology, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN, 55905, USA

Received 13 January 1999; Revised 15 July 1999; Accepted 15 November 1999.

Keywords:

chemotherapy, high-grade gliomas, glioblastoma multiforme, anaplastic astrocytoma, oligodendroglioma, oligoastrocytoma

Top

References

  1. Ameri A, Poisson M and Chen QM (1993) Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. J Neuro-Oncol 17: 43–46
  2. Barba D, Saris SC and Holder C (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70: 175 | PubMed | ISI | ChemPort |
  3. Belanich M, Pastor M and Randall T (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783–788 | PubMed |
  4. Beretta L, Gingras A-C, Svitkin YV, Hall MN and Sonenberg N (1996) Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. Embo J 15: 6578–6664
  5. Berger MS, Prados MD and Van Gilder JC (1997) Phase II Trial of GLI 328 HSV-TK gene therapy in recurrent glioblastoma. Cancer Gene Ther 4: 542
  6. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S and Muna M (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumors cells. Science 274: 373–376 | Article | PubMed | ISI | ChemPort |
  7. Bleehen NM, Roberts JT and Senanayake F (1998) Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high grade glioma (HGG)-BR05. Proc Am Soc Clin Oncol 17: 400a
  8. Bower M, Newlands ES and Bleehen NM (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40: 484–488 | Article | PubMed | ISI | ChemPort |
  9. Brada M and Sharpe G (1996) Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old?. Eur J Cancer 32A: 2193–2194
  10. Brady LW, Miyamoto C and Woo DV (1992) Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 22: 225 | PubMed | ISI | ChemPort |
  11. Brem H, Domb A and Lenartz D (1992) Brain biocompatibility of a biodegradable controlled release polymer consisting of anhydride copolymer of fatty acid and sebacic acid. J Control Rel 19: 325–330
  12. Brem H, Piantadosi S and Burger PC (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer–Brain Tumor Treatment Group. Lancet 345: 1008–1012 | Article | PubMed | ISI | ChemPort |
  13. Broder LE and Carter SK (1970) Clinical brochure BCNU (NSC-409962) Bethesda, MD
  14. Brown M, Cairncross JG and Vick NA (1990) Differential response of recurrent oligodendrogliomas versus astrocytomas to intravenous melphalan. Neurology 40: 397–398
  15. Buckner JC, Brown LD and Cascino TL (1989) Recombinant alpha-interferon and BCNU in recurrent gliomas. J Biol Response Mod 8: 332–333
  16. Buckner JC, Brown LD and Cascino TL (1990) Phase II evaluation of infusional etoposide and cisplatin in patients with recurrent astrocytoma. J Neuro-Oncol 9: 249–254 | ISI | ChemPort |
  17. Burger P, Vogel F, Green S and Strike T (1985) Glioblastoma multiforme and anaplastic astrocytoma; pathologic criteria and prognostic implications. Cancer 56: 1106–1111 | Article | PubMed | ISI | ChemPort |
  18. Burger P, Scheithauer B and Vogel F (1991) Surgical Pathology of the Nervous System and its Coverings Churchill Livingstone: New York
  19. Cairncross JG and Macdonald DR (1988) Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 23: 360–364 | Article | PubMed | ChemPort |
  20. Cairncross JG and MacDonald DR (1991) Chemotherapy for oligodendroglioma: progress report. Arch Neurol 48: 225
  21. Cairncross JG, Macdonald DR and Ramsay DA (1992) Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31: 78–82
  22. Cairncross G, Macdonald D and Ludwin S (1994) Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013–2021 | PubMed | ISI | ChemPort |
  23. Cascino TL, Brown LD and Morton FM (1988) Evaluation of fludarabine phosphate in patients with recurrent glioma. Am J Clin Oncol 11: 586–588
  24. Chamberlain MC and Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066–2071 | PubMed | ChemPort |
  25. Chamberlain MC, Prados MD and Silver PA (1988) A phase II trial of oral melphalan in recurrent primary brain tumors. Am J Clin Oncol 11: 52–54 | PubMed |
  26. Chang CH, Horton J and Schoenfeld D (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997 | Article | PubMed | ISI | ChemPort |
  27. Chang SM, Kuhn JG and Rizzo J (1998) Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol 16: 2188–2194 | PubMed |
  28. Cloughesy TF, Blaack KL and Gobin UP (1999) Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrent malignant gliomas. Neurosurg 44: 270–278
  29. Cohadon F, Aouad N, Rougier A, Vital C, Rivel J and Dartigues J (1985) Histologic and nonhistologic factors correlated with survival time in supratentorial astrocytic tumors. J Neuro-Oncol 3: 105–111 | ISI | ChemPort |
  30. Cokgor I, Akabani G and Friedman AH (1999) Newly diagnosed malignant glioma patients treated with 131I/anti-tenascin monoclonal antibody (MAB) 81C6 via surgically created resection cavities: Results of a phase I trial. Neuro-Oncol 1: S107
  31. Coyle T, Baptista J and Winfield J (1990) Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. J Clin Oncol 8: 2014–2018 | PubMed | ChemPort |
  32. D'Amato RJ, Loughnan MS, Flynn E and Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085 | Article | PubMed | ChemPort |
  33. Daums-Duport C, Scheithauer B, O'Fallon J and Kelly P (1988) Grading of astrocytomas: a simple and reproducible method. Cancer 62: 2152–2165 | Article | PubMed | ChemPort |
  34. Deutsch M, Green SB and Strike TA (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16: 1389
  35. Dietrich PY, Saas P and Walker PR (1997) Immunobiology of gliomas: new perspectives for therapy. Ann NY Acad Sci 824: 124–440
  36. Dinapoli RP, Brown LD and Arusell RM (1993) Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high grade glioma. J Clin Oncol 11: 1316 | PubMed | ChemPort |
  37. Dolan ME and Pegg AE (1997) O6-benzylguanine and its role in chemotherapy. Clin Cancer Res 3: 837–847 | PubMed | ChemPort |
  38. Domb A, Bogdansky S and Olivi A (1991) Controlled delivery of water soluble and hydrolytically unstable anti-cancer drugs for polymeric implants. Polymer Preprints 32: 219–220
  39. Elliott TE, Buckner JC and Cascino TL (1991) Phase II study of ifosfamide with mesna in adult patients with recurrent diffuse astrocytoma. J Neuro-Oncol 10: 27–30
  40. Elliott TE, Dinapoli RP and O'Fallon JR (1997) Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high-grade astrocytoma. J Neuro-Oncol 33: 239–250
  41. EORTC Brain Tumor Cooperative Group (1985) Effect of AZQ(1,4 Cyclohexadiene-1,4-diacarbamic-acid-2,5-bis 1-aziridynyl-d3, 6 dioxodiethylester) in recurring supratentorial malignant brain gliomas: a phase II study. Eur J Clin Oncol 21: 143–146
  42. Eyre HJ, Quagliana JM and Eltringham JR (1983) Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. J Neuro-Oncol 1: 171–177
  43. Fine HA and Antman KH (1992) High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience. Bone Marrow Transplant 10: 315–321 | PubMed |
  44. Fine HA, Dear KBG and Loeffler JS (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585–2597 | Article | PubMed | ISI | ChemPort |
  45. Fine HA, Figg WD and Jaeckle K (2000) Phase II trials of the antiangiogenic agent thalidomide in patient with recurrent high-grade gliomas. J Clin Oncol 18: 708–715 | PubMed | ISI | ChemPort |
  46. Folkman J and Klagsbrun M (1987) Angiogenic factors. Science 235: 442–447 | Article | PubMed | ISI | ChemPort |
  47. Ford J, Osborn C, Barton T and Bleehen NM (1998) A phase I study of intravenous RMP-7 with carboplatin in patients with progression of malignant glioma. Eur J Cancer 34: 1807–1811
  48. Friedman HS, Petros WP and Friedman AH (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516–1525 | PubMed | ISI | ChemPort |
  49. Fulling K and Garcia D (1985) Anaplastic astrocytoma of the adult cerebrum; prognostic value of histologic features. Cancer 55: 928–931
  50. Galanis E, Buckner JC and Schomberg PJ (1997) Effective chemotherapy for advanced CNS embryonal tumors in adults. J Clin Oncol 15: 2939–2944
  51. Galanis E, Buckner JC and Burch PA (1998) Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group Results. J Clin Oncol
  52. Germain RN and Margulies DH (1993) The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11: 403–450 | Article | PubMed | ISI | ChemPort |
  53. Giannone L and Wolff S (1987) Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 71: 759–761
  54. Gilbert MR, Lunsford LD and Kondziolka D (1993) A phase II trial of continuous infusion chemotherapy, external beam radiotherapy and local boots radiotherapy for malignant gliomas. Proc Am Soc Clin Oncol 12: 176
  55. Glass J, Hochberg FH and Gruber ML (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741 | PubMed | ISI | ChemPort |
  56. Grant R, Slattery J and Gregor A (1994) Recording neurological impairment in clinical trials of glioma. J Neuro-Oncol 19: 37–49
  57. Green SB, Byar DP and Walker MD (1983) Comparisons of carmustine procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121 | PubMed | ISI | ChemPort |
  58. Grossman SA, Wharam M and Sheidler V (1997) Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15: 2596–2603
  59. Grossman SA, Hochberg F and Fisher J (1998) Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 432: 118–126
  60. Gutin PH, Wilson CB and Kumar AR (1975) Phase II study of procarbazine, CCNU and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35: 1398–1404
  61. Hoogstraten B, Gottlieb JA and Caoili E (1973) CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer: phase II study. Cancer 32: 38–43
  62. Jeremic B, Grujmicic D and Jevremovic S (1992) Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 10: 1074–1079 | PubMed | ISI | ChemPort |
  63. Karp DD, Silberman SL and Csudae R (1999) Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc Am Soc Clin Oncol 18: 388a
  64. Kaye A and Laws E (ed) (1995) Brain Tumors: An Encyclopedic Approach Churchill Livingstone: New York
  65. Kessinger A, Lemon HM and Foley JF (1979) VM-26 as a second drug in the treatment of brain gliomas. Cancer Treat Rep 63: 511–512
  66. Kohl NE, Mosser SD and deSolms J (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934 | Article | PubMed | ISI | ChemPort |
  67. Krishna Narla R, Liu X-P, Klis D and Uckun FM (1998) Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-Bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154). Clin Cancer Res 4: 2463–2471 | PubMed | ISI | ChemPort |
  68. Kyritsis AP, Yung WKA, Bruner J, Gleason MJ and Levin VA (1993) The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery 32: 365
  69. Lampert K, Machein U, Machein MR, Conca W, Peter HH and Volk B (1998) Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 153: 429–437 | PubMed | ISI | ChemPort |
  70. Lesser GJ and Grossman S (1994) The chemotherapy of high-grade astrocytomas. Semin Oncol 21: 220–235
  71. Levin VA, Edwards MS and Wright DC (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237–241 | PubMed | ISI | ChemPort |
  72. Levin VA, Silver P and Hannigan J (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321–324 | PubMed | ISI | ChemPort |
  73. Levin VA (2000) Phase II glioma trails with temozolomide combinations and other new agents. Cancer Invest 18: 95–96
  74. Li V, Folkerth R, Watanabe H, Yu C, Rupnick M, Barnes P, Scott R and Black P (1994) Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 344: 82–86 | Article | PubMed | ISI | ChemPort |
  75. Luse S (1960) Electron microscopic studies of brain tumors. Neurology 10: 881–905 | PubMed | ISI | ChemPort |
  76. Macdonald DR, Gaspar LE and Cairncross JG (1990) Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27: 573–574 | Article | PubMed | ChemPort |
  77. Mak M, Fung L and Strasser JF (1995) Distribution of drugs following controlled delivery to the brain interstitium. J Neuro-Oncol 26: 91–102
  78. Markert JM, Medlock M and Gillespie GY (1999) Preliminary report on the use of a genetically-engineered HSV-1 in the treatment of malignant glioma in humans. Neuro-Oncol 1: S106
  79. Mineta T, Rabkin SD and Yazaki T (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1: 938–943 | Article | PubMed | ISI | ChemPort |
  80. Mortimer JE, Crowley J and Eyre H (1992) A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group study 69: 1220–1223
  81. Nelson DF, Diener-West M and Weinstein AS (1986) A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys 12: 1793
  82. Nelson DF, Diener-West M and Horton J (1988) Combined modality approach to treatment of malignant gliomas – re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group. NCI Monogr 6: 279–284
  83. Newlands ES, Blackledge GRP and Slack JA (1992) Phase I trial of temozolomide (CCRG 81045: M & B 3983: NSC 262856). Br J Cancer 65: 287–291 | PubMed | ISI | ChemPort |
  84. Newlands ES, O'Reilly SM and Glaser MG (1996) The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A: 2236–2241
  85. Newlands ES, Stevens MFG and Wedge SR (1997 a) Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat 23: 35–61
  86. Newlands ES, Wedge SR and Porteous JK (1997 b) Temozolomide: drug scheduling in vivo and in combination with radiation. Proc Am Soc Clin Oncol 16: 393
  87. O'Reilly MS (1997) Angiostatin. An endogenous inhibitor of angiogenesis and of tumor growth. Regulation of Angiogenesis Goldberg ID, Rosen EM (eds) Birkhauser Verlag: Basel, Switzerland
  88. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G and Lane WS (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285 | Article | PubMed | ISI | ChemPort |
  89. Oldfield EH, Ram Z and Culver KW (1993) Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4: 39–69 | PubMed | ISI | ChemPort |
  90. Osaba D, Aaronson N and Sneeuw K (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer specific questionnaires. Qual Life Res 5: 139–150 | Article | PubMed | ISI | ChemPort |
  91. Petersdorf SH and Berger MS (1996) Concepts in neurosurgery: the molecular basis of neurosurgical disease. Molecular Basis of Chemotherapy for Brain Tumors Raffel C, Harsh GR (eds) pp 198–210, Williams and Wilkins: Baltimore
  92. Phillips G, Wolff S and Fay J (1986) Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J Clin Oncol 4: 639–645 | PubMed | ISI | ChemPort |
  93. Plate K, Breier G, Weich H and Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 59: 520–529 | Article | PubMed | ISI | ChemPort |
  94. Prados M, Scott C and Sandler H (1997) Phase III randomized study of radiotherapy with or without PCV for the treatment of anaplastic astrocytoma: RTOG 9404 interim report. Proc ASTRO 138
  95. Prados M, Yung A and Chang S (1999) A phase 2 trial of Temodal® (temozolomide) in patients with anaplastic astrocytoma at first relapse. Proc Am Soc Clin Oncol 18: 139a
  96. Rodriguez LA, Prados M and Silver P (1989) Revaluation of procarbazine for the treatment of recurrent malignant central nervous system tumours. Cancer 64: 2420–2423 | Article | PubMed | ChemPort |
  97. Russell D and Rubinstein L (1989) Pathology of Tumors of the Nervous System Williams & Wilkins: Baltimore
  98. Safgren SL, Reid JM, Buckner JC, Rajkumar SV, Rios R and Ames MM (1998) Pharmacokinetics of dacarbazine and its active metabolites MTIC and HMMTIC in patients with recurrent glioma. Proc Am Assoc Cancer Res 39: 327
  99. Sanson M, Ameri A and Monjour A (1996) Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin, and etoposide: a phase II study. Eur J Cancer 32A: 2229–2235
  100. Sebag-Montefiore DJ, Douek E and Kingston JE (1992) Intracranial germ cell tumours: I. Experience with platinum-based chemotherapy and implications for curative chemoradiotherapy. Clin Oncol 4: 345–350
  101. Shapiro WR, Green SB and Burger PC (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group trial 8001. J Neurosurg 71: 1 | PubMed | ISI | ChemPort |
  102. Shapiro WR, Green SB and Burger PC (1992) A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant gliomas. J Neurosurg 76: 772
  103. Siu LL, Hidalgo M and Nemunaitis J (1999) Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358, 774: a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol 18: 388a
  104. Spence AM, Berger MS and Livingston RB (1992) Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. J Neuro-Oncol 12: 187–191
  105. Takamiya Y, Brem H, Ojeifo J, Mineta T and Martuza RL (1994) AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurg 34: 869–875
  106. Tirelli U, D'Incalci M and Canetta M (1984) Etoposide (VP-16-213) in malignant brain tumors: a phase II study. J Clin Oncol 2: 432–437 | PubMed |
  107. Walker MD and Hurwitz BS (1970) BCNU 1,3-bis (2-chloroethyl)-1-nitrosourea, (NSC-409962) in the treatment of malignant brain tumor. A preliminary report. Cancer Chemother Rep 54: 263–271 | PubMed | ISI | ChemPort |
  108. Walker MD, Alexander E and Hunt WE (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J Neurosurg 49: 333 | PubMed | ISI | ChemPort |
  109. Walker MD, Green SB and Byar DP (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323 | PubMed | ISI | ChemPort |
  110. Weber F, Floeth F and Rommel F (1999) Topic treatment of malignant glioma by intratumoral administration of IL-4-toxin. Neuro-Oncol 1: S105
  111. Wilson CB, Bodrey EB and Enot KJ (1970) 1,3-bis (2-chloroethyl)-1-nitrosourea (NSC-409962) in the treatment of brain tumors. Cancer Chemother Rep 54: 273–281 | PubMed | ISI | ChemPort |
  112. Witters L, Kumar R and Mandal M (1997) Antisense oligonucleotides to the epidermal growth factor receptor. Proc Am Assoc Cancer Res 38: 315
  113. Yoneda T, Lyall RM and Alsina MM (1991) The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro in the nude mice. Cancer Res 51: 4430 | PubMed |
  114. Yoshida S, Tanaka R, Takai N and Ono K (1990) Adoptive immunotherapy with LAK cells and interleukin-2 in the treatment of recurrent malignant gliomas. Curr Ther Res 47: 654
  115. Yung WK, Harris MI and Bruner JM (1989) Intravenous BCNU and AZQ in patients with recurrent malignant gliomas. J Neuro-Oncol 7: 237–240
  116. Yung WK, Mechtler L and Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 9: 860–864 | PubMed | ISI | ChemPort |
  117. Yung A, Levén VA and Albright R (1999) Randomized trial of temodal (TEM) vs. procarbazine (PCB) in glioblastoma multiforme (GBM) at first relapse. Proc Am Soc Clin Oncol 18: 139a

Extra navigation

naturejobs

More science jobs
Post a job for free

natureproducts